New research reveals potential dangers of semaglutide-based Ozempic medications
Recent research has identified a concerning connection between the popular weight loss and diabetes drugs Ozempic and Wegovy and a rare eye disorder that may cause blindness. Published in JAMA Ophthalmology, the study highlights the increased risk of non-arteritic anterior ischemic optic neuropathy (NAION) for individuals using these medications.
What is NAION?
NAION is a rare but serious condition caused by reduced blood flow to the optic nerve, which can result in sudden vision loss. The optic nerve, comprised of over a million strands, is critical for transmitting visual information from the eye to the brain.
Although NAION affects only 2 to 10 people per 100,000 annually, it is the second leading cause of optic nerve-related blindness. Currently, there is no effective cure for this condition.
Study findings: Elevated risks with Ozempic and semaglutide use
The study revealed that semaglutide significantly increases the likelihood of developing NAION. Diabetes patients: Individuals taking semaglutide for diabetes management were found to be four times more likely to develop NAION than those on other medications. Among the 710 patients with type 2 diabetes studied, semaglutide users had an 8.9% chance of developing NAION, compared to just 1.8% for those on alternative treatments.
Weight loss patients: The risk was even higher for those using semaglutide for weight loss, with a seven-fold increased risk. Patients using semaglutide for obesity had a 6.7% chance of developing NAION, compared to 0.8% for those on other weight loss treatments.
Expert caution: Balancing risks and benefits
Despite the alarming findings, researchers are not recommending patients stop taking semaglutide-based medications. “To be perfectly clear, I would not take my findings and use them to recommend that patients stop taking their medications,” said Dr. Rizzo, the study’s lead researcher. “Our finding was really the first possible significant negative finding with these drugs. It may just merit extra caution in the consideration between doctors and patients about who may use this medicine.”
The study emphasizes the importance of weighing the benefits of semaglutide in managing diabetes and obesity against the potential risks. Patients are encouraged to consult their healthcare providers to discuss the findings and determine the best course of action.
As Ozempic and Wegovy continue to gain popularity, this study serves as a reminder of the importance of ongoing research and informed decision-making in the use of breakthrough medications.
